Rajiv Panwar

Rajiv Panwar's Title

Rajiv Panwar holds the esteemed position of Vice President (VP), Chemistry, Manufacturing, and Controls (CMC) and Clinical Supply Chain. In this role, Rajiv is responsible for overseeing the entire lifecycle of pharmaceutical product development, from initial formulation through to commercial production. His extensive expertise in CMC ensures that products meet the highest standards of quality, safety, and efficacy. Rajiv's leadership in clinical supply chain management ensures that clinical trial materials are readily available, enabling timely and efficient clinical studies.

Rajiv Panwar's Education and Expertise

Rajiv Panwar's academic journey began with a Bachelor of Science in Pharmaceutical Sciences from MD University in India. He further advanced his knowledge and expertise by earning a Master of Science and a Doctor of Philosophy in Interdisciplinary Pharmaceutical Sciences from Northeastern University in Boston. His interdisciplinary studies have equipped him with a broad understanding of pharmaceutical sciences, allowing him to excel in various roles within the industry. Rajiv's education has provided him with a robust foundation in drug development, regulatory affairs, and clinical supply chain management.

Rajiv Panwar's Background

Rajiv Panwar's career in the pharmaceutical industry began at Akrivis Technologies, where he led the development of innovative technologies aimed at targeting small size tumor lesions and cancer stem cells. His pioneering work resulted in multiple awards from the National Institutes of Health (NIH) and the National Cancer Institute (NCI), highlighting his contributions to cancer research. Rajiv's experience at Akrivis set the stage for his subsequent roles at Magenta Therapeutics and Eleven Biotherapeutics, where he continued to make significant strides in drug development and clinical supply chain management.

Rajiv Panwar's Achievements

Throughout his career, Rajiv Panwar has garnered numerous accolades for his contributions to the pharmaceutical industry. At Akrivis Technologies, his work on targeting small size tumor lesions and cancer stem cells earned multiple NIH/NCI awards, underscoring his innovative approach to cancer treatment. His leadership roles at Magenta Therapeutics and Eleven Biotherapeutics further demonstrated his ability to drive successful drug development programs. As VP, CMC and Clinical Supply Chain, Rajiv continues to play a pivotal role in advancing pharmaceutical science, ensuring that new therapies reach patients safely and efficiently.